TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/12/2023
Back to search
Official data from USPTO
MILESTONE PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
MILESTONE PHARMACEUTICALS
ST13
US500000088524189Class
35, 42, 44
Filing
88524189
Registration
7039322
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
07/22/2023
Trademark type
Word
Nice classes
35, 42, 44
Filing date
07/19/2019
Registration date
05/02/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/02/2023
Last transaction
07/22/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
2007-00-00
First use in commerce
2007-00-00
Drawing code
4
Owner type
03
Owner location
Charlotte, NC
Examiner
BECHHOFER, YOCHEVED
Law office
M50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Milestone Pharmaceuticals USA, Inc.
Representatives
Devon E. White WYRICK ROBBINS YATES & PONTON LLP
Technical classification
Nice Classes
Class 35Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 35
Promoting collaboration within the scientificresearch and medical communities to achieve advances in the field of cardiovascular disorders; Promoting the exchange of information and resources within the scientific research and medical communities to achieve advances in the field of cardiovascular disorders
Class 42
Providing medical and scientific research information in the field of heart disease and clinical trials; providing medical and scientific research information in the field of cardiovascular disorders and clinical trials; pharmaceutical research services in the field of heart disease and cardiovascular system; pharmaceutical drug development services in the field of heart disease and cardiovascular system; pharmaceutical research and development in the field of heart disease and cardiovascular system; medical and scientific researchconducting clinical trials for others in the field of heart disease and cardiovascular system; providing medical and scientific research information in the field of pharmaceuticals and clinical trials
Class 44
Providing a resource website featuring information in the field of the treatment of episodic cardiovascular conditions; providing a resource website featuring information for people living with atrial fibrillation/atrial flutter; providing a resource website featuring information for people living with myocardial ischemia including angina; providing a resource website featuring information for people living with supraventricular tachycardias including paroxysmal
Publications
History of USPTO decisions and trademark events.
31 publications found
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
07/12/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
07/12/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/02/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
05/02/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/14/2023
PUBO
PUBLISHED FOR OPPOSITION
02/14/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/25/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/12/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/31/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/31/2022
ALIE
ASSIGNED TO LIE
12/31/2022
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
11/04/2022
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
05/08/2022
GNFR
FINAL REFUSAL E-MAILED
05/08/2022
CNFR
FINAL REFUSAL WRITTEN
05/08/2022
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
10/01/2021
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
04/01/2021
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
10/01/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
04/01/2020
GNSL
LETTER OF SUSPENSION E-MAILED
04/01/2020
CNSL
SUSPENSION LETTER WRITTEN
04/01/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/25/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/24/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/24/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/24/2019
GNRT
NON-FINAL ACTION E-MAILED
09/24/2019
CNRT
NON-FINAL ACTION WRITTEN
09/24/2019
DOCK
ASSIGNED TO EXAMINER
09/22/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/29/2019
NWAP
NEW APPLICATION ENTERED
07/23/2019
Continuous trademark protection
Get notified about every new filing that threatens MILESTONE PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.